Proactive AI-based ICU patient monitoring cleared for market

The FDA has OK’d AI software that can predict worsening condition in ICU patients up to eight hours before the falloff produces symptoms.

Clew Medical announced the market readiness of its ClewICU this week. The company says the technology works by recognizing hemodynamic instability, a disruption in the flow of blood through the body. It receives the relevant data from electronic medical records as well as from bedside monitoring devices.

The system analyzes these data streams in near real-time to “present calculated insights and notifications for dedicated AI models and [provide] a picture of overall unit status,” Clew Medical states.

The toolkit also points out ICU patients who are not in danger of increasing hemodynamic instability. Clew Medical notes this capability can facilitate smarter resource consumption in the ICU.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.